← Leaderboards
Carolyn Timberlake Thorpe
University Of Wisconsin-Madison
$2,721,576
Attributed
$2,721,576
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $649.6K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,721,576 · 3
VA$0 · 2
By mechanism
R01$1,883,720 · 1
R21$837,856 · 2
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Lauren A Trepanier$7,711,987
- Marin Leigh Schweizer$4,424,967
- Susan C Pitt$2,329,214
- Heather B Neuman$3,392,239
- Susan Zelasko$78,704
Others in their field
Top investigators on “Provider”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,562,893,282
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$697,762,662
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$562,749,658
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
ProviderVariantPatternQuality Of CarePharmaceutical PreparationsReportingMedicare ClaimEventGuidelinesAreaEnsureSelection BiasMedicareCaringTreatment GuidelinesAdultInterviewElderlyHealthcareHigh RiskData SetCohortHospitalizationLink
Grant awards (17)
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias$616,553
R01 · FY2025 · AG · contact PI
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias$617,564
R01 · FY2024 · AG · contact PI
Use and costs of low-value health services by Veterans in VA and non-VA settings$0
I01 · FY2024 · VA · contact PI
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias$649,603
R01 · FY2023 · AG · contact PI
Use and costs of low-value health services by Veterans in VA and non-VA settings$0
I01 · FY2023 · VA · contact PI
Use and Effectiveness of Infection Prophylaxis Strategies in a National Cohort of Patients with ANCA Vasculitis$155,500
R21 · FY2022 · AI · contact PI
De-Intensifying Unnecessary Medications in VA CLC Residents Nearing End of Life$0
I01 · FY2022 · VA · contact PI
Use and costs of low-value health services by Veterans in VA and non-VA settings$0
I01 · FY2022 · VA · contact PI
Use and Effectiveness of Infection Prophylaxis Strategies in a National Cohort of Patients with ANCA Vasculitis$272,125
R21 · FY2021 · AI · contact PI
De-Intensifying Unnecessary Medications in VA CLC Residents Nearing End of Life$0
I01 · FY2021 · VA · contact PI
De-Intensifying Unnecessary Medications in VA CLC Residents Nearing End of Life$0
I01 · FY2020 · VA · contact PI
Use and costs of low-value health services by Veterans in VA and non-VA settings$0
I01 · FY2020 · VA · contact PI
De-Intensifying Unnecessary Medications in VA CLC Residents Nearing End of Life$0
I01 · FY2019 · VA · contact PI
De-Intensifying Unnecessary Medications in VA CLC Residents Nearing End of Life$0
I01 · FY2019 · VA · contact PI
De-Intensifying Unnecessary Medications in VA CLC Residents Nearing End of Life$0
I01 · FY2018 · VA · contact PI
Medication Oversupply and Outcomes in Patients with Diabetes$187,481
R21 · FY2011 · DK · contact PI
Medication Oversupply and Outcomes in Patients with Diabetes$222,750
R21 · FY2010 · DK · contact PI